Abstract
Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Current Drug Therapy
Title:Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study
Volume: 8 Issue: 3
Author(s): Philippe Bareille, Ann Allen, Kelly Hardes and Alison Donald
Affiliation:
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Abstract: Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Export Options
About this article
Cite this article as:
Bareille Philippe, Allen Ann, Hardes Kelly and Donald Alison, Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113089990005
DOI https://dx.doi.org/10.2174/15748855113089990005 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Immunologic Impact of Nutrient Depletion in Chronic Obstructive Pulmonary Disease
Current Drug Targets Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Immunity Modulators, Repurposed Drugs and Candidate Vaccines for COVID-19: A Review
Coronaviruses Efficacy and Safety Evaluation of Fixed Dose Combination of Cefepime and Amikacin in Comparison with Cefepime Alone in Treatment of Nosocomial Pneumonia Patients
Current Clinical Pharmacology Drug Repositioning: A Unique Approach to Refurbish Drug Discovery
Current Drug Discovery Technologies Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective
Current Pharmacogenomics and Personalized Medicine The Role of Antihistamine Drugs in Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mining for Protein Kinase Substrates: Integration of Biochemistry, Genetics and Proteomics
Current Proteomics Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery A Review of Fish Lectins
Current Protein & Peptide Science Immunological Mechanism and Clinical Application of PAMP Adjuvants
Recent Patents on Anti-Cancer Drug Discovery Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Growing up in the Web of Social Networking: Adolescent Development and Social Media
Adolescent Psychiatry Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial (Thematic Issue: Emerging Formulation Design and Drug Delivery Systems for Inhaled Therapy)
Current Pharmaceutical Design